About
Dr. Yusaf (PJ) Saleeby shares insights from his practice in 2025 regarding Low Dose Naltrexone (LDN). He discusses patient sensitivity, optimal starting doses, and LDN's efficacy for various conditions including Lyme, cancer, and autoimmune diseases. The conversation also delves into Mast Cell Activation Syndrome (MCAS) and the critical role of informed clinicians in its management.